Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Foghorn Therapeutics is set to release its Q2 2025 earnings results on August 14th, with analysts predicting a loss of ($0.32) per share.
• In the previous quarter, Foghorn reported ($0.28) earnings per share, surpassing expectations and generating revenue of $7.56 million.
• Analysts currently maintain a consensus Buy rating for the company, with an average target price of $12.13.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Foghorn Therapeutics to post earnings of ($0.32) per share for the quarter.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03. The business had revenue of $7.56 million for the quarter, compared to analyst estimates of $7.62 million. On average, analysts expect Foghorn Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foghorn Therapeutics Stock Performance

Shares of NASDAQ:FHTX traded down $0.40 during midday trading on Friday, hitting $4.58. 71,553 shares of the company's stock traded hands, compared to its average volume of 122,213. The company has a market cap of $258.91 million, a PE ratio of -3.85 and a beta of 3.05. The firm's fifty day moving average price is $5.13 and its two-hundred day moving average price is $4.59. Foghorn Therapeutics has a twelve month low of $2.94 and a twelve month high of $10.25.

Hedge Funds Weigh In On Foghorn Therapeutics

An institutional investor recently bought a new position in Foghorn Therapeutics stock. AQR Capital Management LLC acquired a new position in Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The fund acquired 18,693 shares of the company's stock, valued at approximately $68,000. 61.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on FHTX shares. JMP Securities restated a "market outperform" rating and set a $9.00 target price on shares of Foghorn Therapeutics in a report on Thursday, May 15th. Citizens Jmp started coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $9.00 target price on the stock. HC Wainwright upgraded shares of Foghorn Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Finally, Citigroup assumed coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They set an "outperform" rating on the stock. One analyst has rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Foghorn Therapeutics has a consensus rating of "Buy" and an average target price of $12.00.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.